


**Clinical features of CMT2 due to mitofusin 2 mutations**

**K6353**



Lawson et al. describe the clinical features in three families with CMT2 associated with novel mutations in the mitofusin 2 gene, a common cause of axonal CMT (23% of cases). Affected individuals showed age-independent variability of expression, and clinical examination was more sensitive than electrophysiology in identifying patients.

**see page 197**

*The accompanying editorial by Mary M. Reilly places this newly characterized cause of CMT2 into context of CMT 1 and the 15 or more other causes of CMT 2. The GTPase, mitofusin 2 gene (MFN2) (a gene encoding MFN2, a mitochondrial fusion protein), is the primary gene mutated in CMT2A. MFN2 mutations cause a classical CMT2 phenotype: distal predominant lower limb wasting and weakness, sensory loss, and hyporeflexia. An important clinical point identified by Lawson et al. is the greater sensitivity of the clinical examination in determining affected status vs neurophysiology—confirming the impression of clinicians evaluating CMT2.*


**see page 186**

**Infantile spasms and intellectual outcomes in tuberous sclerosis complex**

Goh et al. found that 64% of 50 patients with tuberous sclerosis complex with a history of infantile spasms had mental retardation. Risk factors included a prolonged duration of infantile spasms, prolonged time from treatment initiation to spasms cessation, and poor control of subsequent seizures following infantile spasms.

**see page 235**

**Neurocysticercosis, major contributor to seizures in Peru**



Neurocysticercosis is commonly seen in individuals with seizures in endemic areas. Montano et al. studied 903 residents of an endemic area in Peru and found clear associations among seizures, serology, and CT findings. In this area, neurocysticercosis is a common cause of seizures.

**see page 229**

**Metabolic syndrome and intracranial atherosclerosis**

Bang et al. showed that metabolic syndrome, but not conventional risk factors, was independently associated with intracranial atherosclerosis. Treatment of metabolic abnormalities may be an important prevention strategy for intracranial atherosclerosis.

**see page 296**

*The accompanying editorial by Bushnell and Guzick notes that the metabolic syndrome includes three or more of the following: abdominal obesity, elevated triglycerides ( $\geq 150$  mg/dL) or fasting glucose ( $\geq 110$  mg/dL), low high density lipoprotein cholesterol ( $< 40$ mg/dL for men,  $< 50$  mg/dL for women), and hypertension (systolic BP  $< 130$  mm Hg, diastolic BP  $> 85$  mm Hg, or use of antihypertensive medication). The metabolic syndrome is a risk factor for vascular disease, particularly stroke. The demonstration by Bang et al. of an association between metabolic syndrome and large vessel intracranial disease and the evidence from the recent WASID trial showing that stroke patients with such intracranial disease are at very high risk of recurrent stroke—15% in year 1 and 21% over 2 years for the ASA group and 17% in year 1 and 22% over 2 years for the warfarin group—suggest that recognition and treatment of metabolic syndrome may help to prevent stroke.*

**see page 188**

## Initial diagnoses given to persons with FXTAS

Hall et al. find that persons with the recently described fragile X-associated tremor/ataxia syndrome (FXTAS) were initially given multiple, varied diagnoses. They suggest guidelines for selecting patients for diagnostic testing.

see page 299

## Very fragile FXTAS

O'Dwyer et al. report a woman carrier of the FMR1 gene in the premutation range, who presented with tremor and severe gait ataxia following treatment with carboplatin-containing chemotherapy.

see page 331

*The accompanying editorial by Kamm and Gasser notes that Fragile X syndrome (FXS) is the most common inherited cause of mental retardation. It is caused by an expansion of a CGG trinucleotide repeat in the 5'UTR of the FMR1 gene on the X chromosome to more than 200 repeats (full mutation). Mothers of patients with Fragile X syndrome typically are not mentally retarded but carry an FMR1 repeat expansion between 55 and 200 repeats (premutation). The Fragile X associated tremor ataxia syndrome (FXTAS) has been identified in male premutation carriers, typically grandfathers of boys with FXS who had passed on the premutation to their daughters. FXTAS includes progressive intention tremor and gait ataxia. Less constant features include mild parkinsonism, peripheral neuropathy, autonomic dysfunction, and mild cognitive deficits. T2 hyperintensities in the middle cerebellar peduncles (the "MCP sign") are observed in many patients. It is reasonable to test patients for FXTAS if there is 1) unexplained cerebellar ataxia in males >50 or 2) action tremor, parkinsonism, or dementia in males >50 with either a family history of mental retardation or the MCP sign on MRI.*

see page 190

There is a Patient Page on this topic: [www.neurology.org](http://www.neurology.org)

## Lower mortality of patients with ischemic stroke on lipid-lowering agents

Elkind et al. found that among 650 patients with ischemic stroke, 90-day mortality was lower in those already prescribed lipid-lowering agents at the time of their stroke (1.8% vs 10.6%). In 90% of the patients the agents were HMG-CoA reductase inhibitors—statins.

see page 253

## Decreases in CSF A $\beta$ 42 levels precede cognitive decline in FAD

Moonis et al. report that presymptomatic subjects with pathologic PS1 mutations demonstrate low A $\beta$ 42 levels preceding cognitive decline by many years providing an opportunity to test putative therapies before clinical symptoms develop.

see page 323

### NEUROLOGY INVITES "CLINICAL TRIALS RECRUITING" ANNOUNCEMENTS

*Neurology* now publishes a "Clinical Trials Recruiting" print and online section. This section is prominently displayed on the cover, in the Table of Contents, and on the *Neurology* Web site home page.

*Neurology* has the widest readership of any neurological journal, and *Neurology* online receives heavy traffic from the public. This online section has open access and is featured on the *Neurology* home page.

Line ads can be placed at no charge and display ads [full or 1/2 page] can also be placed for a fee. The ad must be IRB approved before submission. Contact [ctrecruiting@urmc.rochester.edu](mailto:ctrecruiting@urmc.rochester.edu) or click on "Clinical Trials Recruiting" on the home page [[www.neurology.org](http://www.neurology.org)] for more information.

# Neurology<sup>®</sup>

## July 26 Highlights

*Neurology* 2005;65;184-185  
DOI 10.1212/WNL.65.2.184

**This information is current as of July 25, 2005**

**Updated Information & Services**

including high resolution figures, can be found at:  
<http://n.neurology.org/content/65/2/184.full>

**Permissions & Licensing**

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:  
[http://www.neurology.org/about/about\\_the\\_journal#permissions](http://www.neurology.org/about/about_the_journal#permissions)

**Reprints**

Information about ordering reprints can be found online:  
<http://n.neurology.org/subscribers/advertise>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

